Profusa Finalizes Merger, Secures $22.2M Convertible Note Facility

Ticker: NVACW · Form: S-1 · Filed: Aug 29, 2025 · CIK: 1859807

Profusa, INC. S-1 Filing Summary
FieldDetail
CompanyProfusa, INC. (NVACW)
Form TypeS-1
Filed DateAug 29, 2025
Risk Levelhigh
Pages16
Reading Time19 min
Key Dollar Amounts$22,222,222, $10, $10,000,000, $2,222,222, $2,000,000
Sentimentbearish

Sentiment: bearish

Topics: S-1 Filing, Convertible Notes, Dilution Risk, Biotechnology, Medical Devices, PIPE Financing, Nasdaq Listing, Emerging Growth Company

Related Tickers: NVACW, PFSA

TL;DR

**Profusa's S-1 reveals a highly dilutive convertible note deal with Ascent, signaling significant financial risk for common shareholders as the company funds its ambitious bio-sensor pipeline.**

AI Summary

Profusa, Inc. (formerly NorthView Acquisition Corporation) completed its business combination on July 11, 2025, becoming a wholly-owned subsidiary. The company is developing biointegrated sensors, with its Lumee Oxygen Platform already available in the EU for monitoring tissue oxygen levels in conditions like peripheral artery disease and chronic wounds. Its primary R&D focus is the Lumee Glucose Platform, a continuous glucose monitor designed for long-term use with a single injection. On February 11, 2025, Profusa entered into a PIPE Subscription Agreement with Ascent Partners Fund LLC for up to $22,222,222 in senior secured convertible notes, reflecting a 10% original issue discount, for an aggregate purchase price of up to $20,000,000. An initial note of $10,000,000 principal amount was issued on July 11, 2025, for $9,000,000. This note matures on January 11, 2027, carries a 10% annual interest rate (24% upon default), and is convertible at the lower of $10 or 95% of the 10-day VWAP, with down-round protection. On August 25, 2025, the PIPE Subscription Agreement was amended to structure the remaining $12,222,222 into three additional tranches, subject to various conditions including Nasdaq listing compliance and prior tranche repayment/conversion. The conversion price for the Initial Note was also amended on August 25, 2025, to be the lower of the original conversion price or 95% of the 10-day VWAP, with a floor price of 20% of the August 22, 2025 closing sale price.

Why It Matters

This S-1 filing details Profusa's post-merger capital structure and its reliance on convertible debt financing from Ascent Partners Fund LLC, which could significantly dilute existing shareholders. The complex tranche structure and conversion terms, including down-round protection and a 9.99% beneficial ownership limit waiver, indicate a high degree of investor protection for Ascent, potentially at the expense of other investors. For employees and customers, the financing provides capital for continued development of the Lumee Oxygen and Glucose Platforms, critical for bringing innovative biointegrated sensor technology to market. The competitive landscape for continuous glucose monitoring (CGM) is intense, and Profusa's ability to execute on its long-term, single-injection CGM could be a game-changer if successful, but the current financing terms suggest a challenging path.

Risk Assessment

Risk Level: high — The company's reliance on a $22,222,222 convertible promissory note facility with Ascent Partners Fund LLC, featuring a conversion price at the lower of $10 or 95% of the 10-day VWAP with down-round protection, presents substantial dilution risk. The increase of the Beneficial Ownership Limitation from 4.99% to 9.99% for Ascent, waived on August 1, 2025, further concentrates potential control and conversion power. Additionally, an event of default on the note triggers an interest rate increase to 24% per annum, indicating significant financial strain if operational targets are not met.

Analyst Insight

Investors should exercise extreme caution due to the high dilution potential from the convertible notes and the aggressive financing terms. Monitor the stock's VWAP closely, as it directly impacts Ascent's conversion price. Consider the company's ability to meet the conditions for the subsequent tranches and avoid Nasdaq listing deficiencies, as failure could trigger adverse terms or limit future funding.

Financial Highlights

debt To Equity
N/A
revenue
$0
operating Margin
N/A
total Assets
$14.5M
total Debt
$9.0M
net Income
$-15.7M
eps
$-0.22
gross Margin
N/A
cash Position
$1.2M
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What is Profusa, Inc.'s primary business focus after its business combination?

Profusa, Inc. is primarily focused on developing a new generation of biointegrated sensors. Its current offerings include the Lumee Oxygen Platform for tissue oxygen monitoring in the EU and the Lumee Glucose Platform, a continuous glucose monitor under development, designed for long-term use with a single injection.

Who is the selling stockholder in Profusa's S-1 filing and what are they selling?

The selling stockholder is Ascent Partners Fund LLC. They are registering to resell up to 222,222,222 shares of Profusa's Common Stock, which are issuable upon the conversion of certain convertible promissory notes with an aggregate principal value of $22,222,222.

What are the key terms of the convertible notes issued by Profusa to Ascent Partners Fund LLC?

The convertible notes have an aggregate principal amount of up to $22,222,222, issued with a 10% original issue discount. They mature on January 11, 2027, accrue interest at 10% per annum (24% upon default), and are convertible at the lower of $10 or 95% of the lowest 10-day VWAP, with down-round and MFN protections.

How does the Beneficial Ownership Limitation impact Ascent Partners Fund LLC's investment in Profusa?

The Beneficial Ownership Limitation restricts Ascent from converting notes if it would result in owning more than 4.99% of Profusa's outstanding common stock. However, on August 1, 2025, this limit was increased to 9.99% and the 60-day notice requirement was waived, allowing Ascent to potentially convert more shares and increase its stake.

What is the significance of the August 25, 2025 amendments to Profusa's PIPE Subscription Agreement?

The August 25, 2025 amendments restructured the remaining $12,222,222 of the PIPE financing into three additional tranches, each subject to specific conditions like Nasdaq listing compliance, effectiveness of a registration statement, and prior tranche repayment or conversion. This indicates a phased funding approach tied to company performance and regulatory milestones.

Will Profusa, Inc. receive any proceeds from the sale of shares by the Selling Stockholder?

No, Profusa, Inc. will not receive any proceeds from the sale of its Common Stock by Ascent Partners Fund LLC, the Selling Stockholder, as stated in the prospectus.

What is the current listing status and stock price of Profusa's common stock?

Profusa's common stock is listed on the Nasdaq Global Market under the symbol 'PFSA'. On August 28, 2025, the last sale price for its common stock was $0.41 per share.

What are the potential risks associated with investing in Profusa's securities?

Investing in Profusa's securities involves a high degree of risk, as highlighted in the S-1 filing. Key risks include significant dilution from the convertible notes, the company's reliance on future tranches of financing, and the potential for a 24% interest rate upon an event of default on the notes.

What is the 'Floor Price' mentioned in the Note Amendment for Profusa's convertible notes?

The 'Floor Price' is a minimum conversion price for the Initial Note, set at twenty percent (20%) of the closing sale price of Profusa's common stock on the principal trading market on August 22, 2025. This provision aims to prevent the conversion price from falling below a certain threshold, even with the VWAP discount.

When did Profusa, Inc. complete its business combination and change its name?

Profusa, Inc. completed its business combination on July 11, 2025. In connection with this closing, the company changed its name from 'NorthView Acquisition Corporation' to 'Profusa, Inc.'.

Risk Factors

Industry Context

Profusa operates in the rapidly evolving medical device sector, specifically focusing on biointegrated sensors for health monitoring. The market for continuous glucose monitoring (CGM) is highly competitive, dominated by established players. However, there is a growing demand for long-term, less invasive monitoring solutions, creating opportunities for innovative technologies like Profusa's Lumee Glucose Platform.

Regulatory Implications

As a developer of medical devices, Profusa will face stringent regulatory hurdles, particularly for its Lumee Glucose Platform, which will likely require FDA approval in the US and similar approvals in other major markets. Compliance with healthcare data privacy regulations (e.g., HIPAA) is also critical. The company's ability to secure Nasdaq listing compliance is a prerequisite for accessing further financing.

What Investors Should Do

  1. Monitor Nasdaq Listing Compliance
  2. Analyze Dilution Potential
  3. Evaluate Commercialization Progress
  4. Assess Cash Burn and Runway

Key Dates

Glossary

PIPE
Private Investment in Public Equity. A transaction where institutional investors purchase securities directly from a public company. (Profusa secured financing through a PIPE transaction with Ascent Partners Fund LLC.)
Senior Secured Convertible Notes
Debt instruments that are senior in repayment priority, secured by company assets, and can be converted into equity. (The financing from Ascent Partners Fund LLC is structured as these types of notes, indicating potential future dilution.)
Original Issue Discount (OID)
The difference between the face value of a debt instrument and the lower price at which it is issued. (Profusa issued notes with a 10% OID, meaning they received $9M for $10M in principal, increasing the effective cost of capital.)
VWAP
Volume Weighted Average Price. The average price of a security over a given period, weighted by trading volume. (The conversion price of the notes is tied to VWAP, with a discount, impacting the potential dilution.)
Down-round Protection
A feature in convertible securities that adjusts the conversion price downward if the company issues new equity at a price lower than the original conversion price. (This feature protects the investor from dilution in a falling stock price scenario, potentially increasing dilution for existing shareholders.)
Tranche
A portion or slice of a larger offering or financing. (The Ascent Partners Fund LLC financing is structured into multiple tranches, with subsequent tranches subject to specific conditions.)

Year-Over-Year Comparison

This S-1 filing follows Profusa's business combination and represents its first comprehensive disclosure as a public entity. Therefore, a direct year-over-year comparison of financial metrics like revenue growth, margins, and net income is not possible. Key financial data presented reflects the company's pre-revenue stage, with significant net losses and minimal cash, highlighting the critical reliance on the recently structured PIPE financing to fund future operations and development.

Filing Stats: 4,683 words · 19 min read · ~16 pages · Grade level 17.3 · Accepted 2025-08-29 17:09:51

Key Financial Figures

Filing Documents

RISK FACTORS

RISK FACTORS 5 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 68

USE OF PROCEEDS

USE OF PROCEEDS 69 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION 70 DIVIDEND POLICY 85 MARKET INFORMATION 86

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 87

BUSINESS

BUSINESS 100 MANAGEMENT 127

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 132

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 134 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 136 SELLING STOCKHOLDER 140 PLAN OF DISTRIBUTION 142

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 144 LEGAL MATTERS 148 EXPERTS 148 WHERE YOU CAN FIND MORE INFORMATION 148 INDEX TO FINANCIAL INFORMATION F-1 You should rely only on the information contained in this prospectus or any amendment or supplement to this prospectus. This prospectus is an offer to sell only the securities offered hereby, but only under the circumstances and in jurisdictions where it is lawful to do so. Neither we nor the Selling Stockholder have authorized anyone to provide you with information different from that contained in this prospectus or any amendment or supplement to this prospectus. Neither we nor the Selling Stockholder take any responsibility for, or can provide any assurance as to the reliability of, any information other than the information in this prospectus or any amendment or supplement to this prospectus. The information in this prospectus or any amendment or supplement to this prospectus is accurate only as of its date, regardless of the time of delivery of this prospectus or any amendment or supplement to this prospectus, as applicable, or any sale of the securities offered by this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. For Investors Outside the United States: The Selling Stockholder is offering to sell, and seeking offers to buy, the securities offered by this prospectus only in jurisdictions where offers and sales are permitted. Neither we nor the Selling Stockholder have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities offered by this prospectus and the distribution of this prospectus outside the United States. i Table of C

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing